Connect with us

Life Sciences

Tempo Automation Secures Up To $100 Million in Committed Equity Financing with White Lion Capital

 Tempo Automation (“Tempo”), a leading software-accelerated electronics manufacturer, and ACE Convergence Acquisition Corp. (“ACE”) a special…

Published

on

This article was originally published by AITHORITY
Tempo Automation Secures Up To $100 Million in Committed Equity Financing with White Lion Capital

 Tempo Automation (“Tempo”), a leading software-accelerated electronics manufacturer, and ACE Convergence Acquisition Corp. (“ACE”) a special purpose acquisition company focusing on industrial and enterprise IT, have entered into a committed equity facility with White Lion Capital, LLC (“White Lion Capital”). Under the terms of the facility, White Lion Capital has committed to purchase up to an aggregate of $100 million in the post-closing combined company’s common shares from time to time after the consummation of the previously announced business combination between Tempo and ACE at the request of the post-closing combined company. This facility will provide Tempo with the ability to raise additional capital in the future, subject to certain limitations and conditions.

Latest AI/NLP Technology Insights: ProcessUnity Acquires AI/NLP Technology from ISMS Solutions

As previously announced, Tempo and ACE have entered into an amended and restated agreement and plan of merger relating to the proposed business combination. Upon the closing of the proposed business combination, which is subject to the satisfaction or waiver of the conditions stated in the merger agreement and other customary closing conditions, the combined entity is expected to be renamed “Tempo Automation Holdings, Inc.” and shares of its common stock are expected to trade on The Nasdaq Stock Market LLC under the ticker symbol “TMPO.” Tempo and ACE currently expect the transaction to be closed, subject to respective shareholder approvals, by the end of November 2022.

AI News: An Investment Into Artificial Intelligence as Daktela Buys Coworkers.ai

Tempo is a leading software-accelerated electronics manufacturer, transforming the way top companies innovate and bring new products to market. Tempo Automation’s unique automated manufacturing platform optimizes the complex process of printed circuit board manufacturing to deliver unmatched quality, speed and agility. The platform’s all-digital process automation, data-driven intelligence, and connected smart factory create a distinctive competitive advantage for customers—to deliver tomorrow’s products today. From rockets to robots, autonomous cars to drones, many of the fastest-moving companies in industrial tech, medical technology, space, and other industries partner with Tempo Automation to accelerate innovation and set a new tempo for progress.

ACE Convergence Acquisition Corp. is a special purpose acquisition company focusing on industrial and enterprise IT and semiconductors

Latest Aithority Insights : Got It AI Announces AutoFlows, a Breakthrough Autonomous Conversational AI

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Tempo Automation Secures Up To $100 Million in Committed Equity Financing with White Lion Capital appeared first on AiThority.



artificial intelligence


shares

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending